Blockchain

Merlin Chain Emerges as Bitcoin’s Largest Layer 2, Surpassing $1.2 Billion TVL in Just Six Months

on

    More in Blockchain:

    Singapore, Singapore, September 9th, 2024, Chainwire

     

    Merlin Chain, a revolutionary Bitcoin Layer 2 platform, has achieved unprecedented milestones in just six months, solidifying its position as the largest Layer 2 in the Bitcoin ecosystem. With a Total Value Locked (TVL) surpassing $1.2 billion and bridge transactions exceeding $16 billion, Merlin Chain has redefined how users interact with Bitcoin, empowering native assets, fostering liquidity, and driving innovative ecosystem developments.

    Since its launch in early 2024, Merlin Chain has grown into the largest Bitcoin-native network, with 1.9 million on-chain addresses and over 12.7 million transactions processed. The platform has also become the leading hub for Bitcoin-native assets, hosting over 80% of all Bitcoin-native asset holders.

    Merlin Chain’s remarkable achievements in the first half of 2024 include:

    • Adoption and Network Growth: With rapid TVL growth of $3.9 billion within 50 days of the mainnet launch and 1.9 million unique addresses, Merlin Chain continues to lead the Bitcoin Layer 2 space.
    • Strength in Liquidity: Merlin Chain has facilitated over $16 billion in BTC bridged volume, with $1 billion in spot trading and $1 billion in perpetual trading, securing its position as a key player in Bitcoin liquidity.
    • Thriving Ecosystem: Merlin Chain now supports more than 200 decentralized applications (dApps) across DeFi, BTCFi, gaming, NFTs, and more. Leading platforms such as UniCross, Solv Protocol, Avalon Labs, and MerlinSwap have contributed to this robust ecosystem growth, providing the community with innovative services and liquidity solutions.
    • Fair Token Distribution: Token fairly distributed to the community. $MERL’s inflation slowed significantly, to only 0.4% in the next 12 months.

    210M $MERL Ecosystem Grant to Accelerate Expansion

    To further solidify its leadership, Merlin Chain launched its 210M $MERL Ecosystem Grant Program in June, focusing on enhancing user experience, Bitcoin-native asset innovation, ecosystem engagement, and developer tools. The grant is aimed at expanding the platform’s ecosystem by empowering builders and innovators to contribute to the future of Bitcoin Layer 2.

    Technical Advancements and Security

    Merlin Chain’s commitment to innovation is supported by its advanced technical architecture. The platform has implemented ZK-Rollup technology and multi-token staking Oracle nodes to enhance security, scalability, and transparency. By integrating solutions like Babylon and BTC Staking/Restaking, Merlin Chain is pioneering new ways to optimize Bitcoin-native asset yields.

    Merlin Chain has also partnered with leading security firms such as Celestia for data integrity and Cobo for advanced MPC wallets, ensuring that users have access to cutting-edge technology to safeguard their assets. Additionally, Merlin Chain established the Merlin Security Council, which includes renowned partners like Slowmist and BlockSec, further fortifying its security infrastructure.

    Looking Ahead to 2024

    As Merlin Chain continues to lead in Bitcoin Layer 2 innovation, it is preparing for even greater expansion in the second half of 2024. With plans to integrate Bitcoin’s latest protocol updates and drive further growth in its ecosystem, Merlin Chain aims to become the dominant force in Bitcoin-native assets, liquidity, and interoperability across multiple chains, including EVM, Solana, and TON.

    “We are incredibly proud of the strides we’ve made in such a short time,” said Jeff, Founder of Merlin Chain. “Our success wouldn’t be possible without the support of our community and our innovative partners. As we look ahead, we’re excited to continue pushing the boundaries of what’s possible for Bitcoin and its Layer 2 ecosystem.”

    Users can read Merlin Chain’s full report here: https://drive.google.com/file/d/1PtDSlqIHxAC1eiQXI2vB7DRTSXI-NQR_/view?usp=share_link

    About Merlin Chain

    Merlin Chain is a Bitcoin Layer 2 that integrates the ZK-Rollup network, decentralized oracle network, and on-chain BTC fraud-proof modules. Merlin Chain is committed to empowering Bitcoin’s native assets, protocols, and products on Layer1 through its Layer 2 network to Make Bitcoin Fun Again. Merlin Chain is a subsidiary product line of Bitmap Tech, a premier OG team boasting an overall market cap exceeding $500 million. The BRC-420 “Blue Box” collection under Bitmap Tech has become one of the hottest assets on Ordinals.

    For more information, users can visit Merlin Chain’s Website | Twitter | Discord

     

    Contact

    Head of BD and Partnership
    Jonathan
    Merlin Chain
    contact@merlinchain.com

    PostAd_coinrule_banner728x90

    Leave a Comment

    Your email address will not be published. Required fields are marked *

    *

    PersonalAIze and Cube Forge Groundbreaking Partnership to Accelerate AI-Driven Healthcare Platform and Point of Care Diagnostics

    2024-09-19T13:00:00Z

    Strategic partnership aims to further develop Cube’s award-winning AI guided platform for Software as a Service (SaaS) for the private sector and large healthcare systems and diagnostic to support clinicians and patients in making informed therapeutic decisions from early detection to personalized treatment and disease monitoring, for improved health outcomes

    AMSTERDAM, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) PersonalAIze and RenovaroCube are proud to announce a strategic partnership to develop, validate, and commercialize Cube’s AI-driven, multi-omic platform for early detection of cancer and other diseases. This strategic partnership aims to provide services to many AI companies and healthcare systems while also creating the next generation of medical diagnostics through cutting-edge AI by driving greater accuracy, transparency, and trust in healthcare solutions.

    Prof. Mark Hoogendoorn, Co-CEO and Co-Founder PersonalAIze: "The strategic partnership between PersonalAIze and Cube has the potential to provide a transformative leap in healthcare diagnostics, uniting cutting-edge AI with trusted, high-performance capabilities and industry related in-depth expertise.”

    Frank van Asch, Founder and CTO of RenovaroCube,” Together, we are pioneering a future where healthcare outcomes are improved by training models for multiple decisions through the entire health journey, ensuring the right accuracy for therapeutic decisions in every disease stage.”

    The first phase of the collaboration focuses on establishing a strong foundation for the partnership, with PersonalAIze providing critical expertise in the integration of AI into healthcare. It will enhance existing collaborations with Academic and corporate partners and create new ones to build an eco-system to help develop and bring to the market a cutting-edge SaaS model and the next generation highly accurate diagnostics, starting with cancer.

    Prof Sandjai Buhlai, Co-CEO and Co-Founder PersonalAIze: “This collaboration signals a bold step forward in utilizing the full potential of AI potentially to help revolutionize early-stage medical interventions and diagnosis at the earliest stage of cancer before imaging has been able to detect the tumors.”

    Key contributions from PersonalAIze include:

    • Ethical AI: Ensuring the AI models are free from harmful biases and trained to support fairness and inclusivity in medical diagnostics.
    • Legal Guidance: Providing expert advice on legal responsibilities tied to AI outputs, including issues of AI accountability and potential liability.
    • Regulatory Compliance: Assisting in navigating existing and emerging regulations such as NEN, ISO, GDPR, and the AI Act, ensuring the platform adheres to all relevant healthcare regulations and clinical guidelines.
    • Medical and Diagnostic Input: Offering support in clinical validation in collaboration with medical scientists to ensure the AI is reliable and effective in real-world medical environments.
    • Explainable AI: Developing AI models that are transparent, fostering trust and confidence from both healthcare providers and patients.

    Key Resources and Support from PersonalAIze
    As part of the collaboration, PersonalAIze will contribute:

    • Expert Personnel: Including a Principal Investigator (PI) to lead clinical AI efforts, a project manager to coordinate the collaboration and a strategic advisor to oversee the scientific strategy and execution.
    • Research and Talent Capacity: Leveraging academic partnerships to ensure access to cutting-edge research and innovation and facilitating talent scouting to support the project’s development.
    • Academic Spin-Out Opportunities: Supporting the commercialization of academic research through potential spin-out ventures related to AI diagnostics.
    • Co-Development of AI Platform: Jointly developing a science-driven, evidence-based AI platform that meets rigorous clinical and regulatory standards.
    • Ongoing Research and Publications: Contributing to the body of research through support with peer-reviewed publications in collaboration with clinical experts that will help build trust within the medical community and among regulatory bodies.
    • Architecture and Strategy Guidance: Continuously advising on the platform’s architecture and strategic direction, ensuring it stays aligned with the latest industry trends and scientific advancements.
    • Trusted AI: Developing a trustworthy, explainable AI platform that inspires confidence among healthcare providers and patients through clear and transparent decision-making processes.

    About PersonalAIze
    PersonalAIze focuses on building solutions that improve healthcare by leveraging state-of-the-art AI techniques. It has been founded by four experienced professors bringing together decades of research experience in AI and healthcare with the aim to bring the latest scientific AI developments into healthcare practice faster. PersonalAIze does this through both consultancy and product development and targets clinical decision-making systems as well as improvement of health care operations such as capacity planning.

    About Renovaro
    Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.

    RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 12-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in disease agnostic decision support.

    Forward-Looking Statements
    Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

    For media inquiries, please contact: karen@renovarocube.com

    Source: Renovaro Inc.


    GlobeNewsWire News

    Recent Comments